This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	HIV gp120; CD4	<p>Human serum studies identified neutralizing antibodies against HIV gp120 that could aid the development of HIV vaccines. <i>In vitro</i> serum assays identified three antibodies that neutralized a conserved CD4-binding epitope of HIV gp120. The three antibodies neutralized 91%, 91% and 57% of a panel of 190 known HIV genetic subtypes. Ongoing and planned work includes testing the ability of the antibodies to block HIV infection in nonhuman primates and investigating their use in HIV microbicides.</p> <p>GeoVax Labs Inc.'s HIV vaccine, consisting of pGA2/JS7 DNA as a primer and recombinant modified vaccinia Ankara (MVA)/HIV62 as a booster, is in Phase IIa and Phase I testing to prevent and treat HIV infection, respectively.</p> <p>GenVec Inc.'s VRC-HIVADV014-00-VP, an HIV vaccine that combines synthetically modified elements of HIV genes <i>gag</i>, <i>pol</i>, <i>nef</i> and <i>env</i>, is in Phase II testing to prevent HIV infection.</p> <p>Vical Inc.'s HIV plasmid DNA vaccine encoding modified versions of HIV <i>gag</i>, <i>pol</i>, <i>nef</i> and <i>env</i> is in Phase II testing to prevent or treat HIV infection.</p> <p>SciBX 3(28); doi:10.1038/scibx.2010.865 Published online July 22, 2010</p>	Patent application filed by the NIH; available for licensing	<p>Wu, X. <i>et al. Science</i>; published online July 8, 2010; doi:10.1126/science.1187659</p> <p>Contact: Gary J. Nabel, National Institute of Allergy and Infectious Diseases, Bethesda, Md. e-mail: gnabel@nih.gov</p> <p>Contact: John R. Mascola, same affiliation as above e-mail: jmascola@nih.gov</p>